On the basis of these findings, multiple strategies using VS-6766/CH5126766 alone (NCT03681483) or with other agents such as defactinib (NCT03875820, NCT04625270, NCT04620330) are currently under clinical investigation in cancers with KRAS mutations. The gene discussed is KRAS; the disease is cancer.